Ferring Pharmaceuticals will launch a new biotech centre in Switzerland

Ferring Pharmaceuticals announced that it is expanding its capabilities in biologics through a new biotech centre which will be installed at the company’s existing headquarters and manufacturing site in Saint-Prex, Switzerland.

Over the next three years, Ferring will invest approximately $32,5 million in the new Ferring Biotech Centre, which will incorporate discovery and development capabilities for monoclonal antibodies as well as biologics manufacturing capabilities.

In addition to the discovery, development and manufacture of new biologics, the active pharmaceutical ingredient (API) for Rekovelle® (follitropin delta), Ferring’s latest fertility treatment, will also be manufactured at the new Ferring Biotech Centre.

Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Founded in 1950, Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.